Press releases

Non Regulatory

December 28, 2023

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Regulatory

December 22, 2023

Vivesto’s Paccal Vet granted FDA MUMS designation

Regulatory

December 22, 2023

Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea

Non Regulatory

December 19, 2023

Vivesto reports positive preclinical data supporting continued development of Cantrixil

Regulatory

November 23, 2023

Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto

Regulatory

November 23, 2023

Vivesto and Elevar sign agreement ending Apealea® partnership

Regulatory

November 16, 2023

Interim report for the period January 1, 2023 – September 30, 2023

Regulatory

October 25, 2023

Vivesto focuses its project portfolio and introduces cost-saving measures

Regulatory

September 15, 2023

Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023

Regulatory

August 24, 2023

Interim report for the period January 1, 2023 – June 30, 2023

Non Regulatory

August 4, 2023

Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study

Non Regulatory

June 16, 2023

Vivesto announces positive Paccal Vet FDA pre-submission meeting

Regulatory

May 25, 2023

Report from Annual General Meeting in Vivesto AB

Regulatory

May 25, 2023

Interim report for the period January 2023 – March 2023

Regulatory

April 25, 2023

Notice of Annual General Meeting in Vivesto AB

Regulatory

April 25, 2023

Vivesto publishes Annual Report for 2022

Regulatory

March 24, 2023

Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party

Non Regulatory

March 20, 2023

Vivesto initiates clinical development of Paccal Vet in veterinary oncology

Regulatory

February 23, 2023

Year-end report for the financial year January 1 – December 31, 2022

Non Regulatory

January 11, 2023

Vivesto announces Inceptua decision to withdraw market authorization application for Apealea® in Switzerland